Ads
related to: life expectancy with hfpef blood disorder treatment- ATTR-CM Treatment
Learn more about a treatment for
ATTR-CM that may help.
- Get Started On Treatment
Find information about getting
started on a treatment for ATTR-CM.
- Learn More About ATTR-CM
Discover more information about
ATTR-CM including signs & symptoms.
- Find Patient Resources
Uncover patient resources including
a doctor discussion guide.
- ATTR-CM Treatment
Search results
Results From The WOW.Com Content Network
Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure in which the ejection fraction – the percentage of the volume of blood ejected from the left ventricle with each heartbeat divided by the volume of blood when the left ventricle is maximally filled – is normal, defined as greater than 50%; [1] this may be measured by echocardiography or cardiac catheterization.
Heart failure (HF), also known as congestive heart failure (CHF), is a syndrome caused by an impairment in the heart's ability to fill with and pump blood.. Although symptoms vary based on which side of the heart is affected, HF typically presents with shortness of breath, excessive fatigue, and bilateral leg swelling. [3]
Thrombotic thrombocytopenic purpura (TTP) is a blood disorder that results in blood clots forming in small blood vessels throughout the body. [2] This results in a low platelet count, low red blood cells due to their breakdown, and often kidney, heart, and brain dysfunction. [1]
Recent research has found that people with diabetes are more susceptible to developing multiple co-occurring long-term conditions, which, in turn, can shorten life expectancy.
It may occur in situations with an increased blood volume, morbid obesity, from excess of water and salt (kidney pathology, excess of fluid or blood administration, treatment with retaining water steroids), chronic and severe anemia, large arteriovenous fistula or multiple small arteriovenous shunts as in HHT or Paget's disease of bone, some ...
A 2014 Canadian study calculated the cost per life-year-gained with treatment as CAN$4.62 million (US$4,571,564) and cost per quality-adjusted-life-year as CAN$2.13 million (US$2,112,398)."The incremental cost per life year and per QALY gained is CAN$4.62 million and CAN$2.13 million, respectively.
Ads
related to: life expectancy with hfpef blood disorder treatment